Cargando…
How we treat endocrine complications of immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) are antibodies that target certain immune checkpoints (ICs), such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death 1 (PD-1) or its ligand (PD-L1), and have emerged as a powerful new tool for oncologists. As these immune checkpoints are cru...
Autores principales: | Paschou, S.A., Stefanaki, K., Psaltopoulou, T., Liontos, M., Koutsoukos, K., Zagouri, F., Lambrinoudaki, I., Dimopoulos, M.-A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807832/ https://www.ncbi.nlm.nih.gov/pubmed/33399077 http://dx.doi.org/10.1016/j.esmoop.2020.100011 |
Ejemplares similares
-
Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
por: Paschou, Stavroula A., et al.
Publicado: (2022) -
Early and late endocrine complications of COVID-19
por: Kazakou, Paraskevi, et al.
Publicado: (2021) -
The emerging role of BET inhibitors in breast cancer
por: Andrikopoulou, A., et al.
Publicado: (2020) -
Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2020) -
Hyponatraemia in patients on immune checkpoint
inhibitors
por: Paschou, Stavroula A., et al.
Publicado: (2022)